Cartesian Therapeutics to Present at Multiple Investor Conferences in September
News provided byCartesian Therapeutics, Inc · 1 min read
FREDERICK, Md., Sept. 03, 2026 /CourierPR/ -- Cartesian Therapeutics, a late-stage biotech firm specializing in cell therapy for autoimmune diseases, will participate in several investor conferences in September 2026, offering insights into its pipeline of treatments.
On Thursday, September 10, the company's management will engage in a fireside chat at the 2026 Cantor Global Healthcare Conference. This event is scheduled for 3:55 p.m. Eastern Time. The following Monday, September 14, management will meet one-on-one and in groups with investors at the Morgan Stanley 24th Annual Healthcare Conference. The conference will take place on Monday, September 14.
On Tuesday, September 15, Cartesian Therapeutics will host another fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, which will begin at 1:30 p.m. Eastern Time. Attendees will have the opportunity to hear directly from the company’s executives about its ongoing clinical development programs.
Live webcasts of these fireside chats will be available on the company’s website at www.cartesiantherapeutics.com. Archival recordings will also be made available for a limited time.
Cartesian Therapeutics is advancing several cell therapies aimed at treating autoimmune diseases. Its lead asset, Descartes-08, is in Phase 3 clinical trials for generalized myasthenia gravis, while other treatments are in Phase 2 and Phase 1/2 stages for conditions like myositis and pediatric autoimmune diseases.
The company’s lead asset, Descartes-08, is currently in Phase 3 clinical trials for generalized myasthenia gravis, Phase 2 for myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 for pediatric autoimmune diseases, including juvenile dermatomyositis.
As the firm prepares to present its progress at these key industry events, investors and healthcare professionals are anticipated to gain deeper insights into the potential of Cartesian Therapeutics’ innovative cell therapies.